Patents Assigned to Kitasato Institute
-
Patent number: 12239619Abstract: The object is to provide a method for inducing pili formation in bacterium of genus Bifidobacterium and a method for promoting intestinal colonization of the bacterium. 3-Phenylpropionic acid and/or 3-(4-hydroxyphenyl)propionic acid are an active ingredient of a composition for inducing the pili formation in the bacterium of genus Bifidobacterium and a composition for promoting the intestinal colonization of the bacterium.Type: GrantFiled: February 28, 2020Date of Patent: March 4, 2025Assignees: Morinaga Milk Industry Co., Ltd., National University Corporation Kobe University, The Kitasato InstituteInventors: Kanetada Shimizu, Ro Osawa, Keita Nishiyama, Nobuhiko Okada, Nobuhiro Koyama, Takao Mukai, Hiroshi Tomoda
-
Patent number: 11624060Abstract: The invention generally relates to collagen-binding agent compositions and methods of using the same. More specifically, the invention relates in part to new collagen-binding agent compositions and methods that may be used to treat damaged collagen within tissues or used to specifically target therapeutics to tissues containing undamaged or damaged collagen.Type: GrantFiled: February 9, 2018Date of Patent: April 11, 2023Assignees: The Board of Trustees of the University of Arkansas, The Kitasato InstituteInventors: Joshua Sakon, Jeffrey Roeser, Ryan Bauer, Katarzyna Janowska, Keisuke Tanaka, Osamu Matsushita, Kentaro Uchida
-
Patent number: 11614418Abstract: A yarn has a first conductive yarn having conductivity, a first insulating section covering the first conductive yarn and formed of an insulating material having absorbency, and a second conductive yarn having conductivity and disposed on an outer circumferential side of the first insulating section.Type: GrantFiled: October 6, 2015Date of Patent: March 28, 2023Assignee: School Juridical Person Kitasato InstituteInventor: Satoru Nebuya
-
Patent number: 11427620Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.Type: GrantFiled: September 4, 2017Date of Patent: August 30, 2022Assignees: Hokusan Co., Ltd., National Institute of Advanced Industrial Science and Technology, School Juridical Person The Kitasato InstituteInventors: Noriko Tabayashi, Toru Gotanda, Hanae Sasaki, Noriko Itchoda, Uiko Kagaya, Takeshi Matsumura, Akira Ito, Hiromi Ikadai
-
Patent number: 11279922Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: GrantFiled: February 22, 2019Date of Patent: March 22, 2022Assignees: The Board of Trustees of the University of Arkansas, The Kitasato Institute, Montefiore Medical Center, National University Corporation Kagawa UniversityInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
-
Publication number: 20210292382Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.Type: ApplicationFiled: September 4, 2017Publication date: September 23, 2021Applicants: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and Technology, School Juridical Person The Kitasato InstituteInventors: Noriko Tabayashi, Toru Gotanda, Hanae Sasaki, Noriko Itchoda, Uiko Kagaya, Takeshi Matsumura, Akira Ito, Hiromi Ikadai
-
Publication number: 20210079110Abstract: Provided is a monoclonal antibody or a fragment thereof in which heavy-chain complementarity-determining regions (CDRs) 1 to 3 respectively consist of amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 respectively consist of amino acid sequences of SEQ ID NOs: 5 to 7; a monoclonal antibody or a fragment thereof in which heavy-chain CDRs 1 to 3 respectively consist of amino acid sequences obtained by deleting, substituting, or adding one or several amino acids in the amino acid sequences of SEQ ID NOs: 2 to 4 and light-chain CDRs 1 to 3 respectively consist of amino acid sequences obtained by deleting, substituting, or adding one or several amino acids in the amino acid sequences of SEQ ID NOs: 5 to 7, and which has binding properties to a KK-LC-1 protein; or a monoclonal antibody or a fragment thereof which competes with the monoclonal antibody or a fragment thereof in which the heavy-chain CDRs 1 to 3 respectively consist of the amino acid sequences of SEQ ID NOs: 2 to 4 and the light-chType: ApplicationFiled: November 9, 2018Publication date: March 18, 2021Applicant: School Juridical Person the Kitasato InstituteInventors: Takashi FUKUYAMA, Hitoshi YAMAZAKI, Mariko OGI, Noritada KOBAYASHI, Yoshinobu ICHIKI, Masahiko HATAKEYAMA
-
Publication number: 20190249163Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: ApplicationFiled: February 22, 2019Publication date: August 15, 2019Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSA S, The Kitasato Institute, MONTEFIORE MEDICAL CENTER, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERISTYInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
-
Patent number: 10213488Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: GrantFiled: December 21, 2016Date of Patent: February 26, 2019Assignees: The Board of Trustees of the University of Arkansas, The Kitasato Institute, Montefiore Medical CenterInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
-
Patent number: 10202627Abstract: An object of the present invention is to provide enzymes and a DNA encoding the enzymes that are involved in biosynthesis of trehangelin which has the potential to be a therapeutic agent for photosensitivity disorder and cosmetics, and to provide a method for producing trehangelin by utilizing the enzymes and a recombinant microorganism. The present invention is directed to a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9, or a protein having an amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 in which one to several amino acids are deleted, substituted, added and/or inserted or an amino acid sequence having 60% or more homology with the amino acid sequence of SEQ ID NO: 3, 5, 7 or 9 and having an enzyme activity involved in biosynthesis of trehangelin; and a DNA encoding said protein.Type: GrantFiled: February 28, 2017Date of Patent: February 12, 2019Assignees: The Kitasato Institute, Nagase & Co., Ltd.Inventors: Satoshi Omura, Yoko Takahashi, Takuji Nakashima, Yuki Inahashi
-
Patent number: 9896456Abstract: This invention provides a novel non-natural pharmaceutical compound having a different mechanism than statin drugs and having a selective inhibitory activity against ACAT2.Type: GrantFiled: June 18, 2015Date of Patent: February 20, 2018Assignee: School Juridical Person Kitasato InstituteInventors: Hiroshi Tomoda, Masaki Ohtawa, Satoshi Omura, Tohru Nagamitsu
-
Patent number: 9737558Abstract: The present invention provides a Peyer's patch activator containing a polysaccharide obtained from sugar cane as an active ingredient, wherein the polysaccharide contains ?-glucan as a main component and has a peak molecular weight within a range of 720,000 to 1,080,000, with a proportion of glucose in all component sugars being 80% or more, and proportions of nonreducing terminal glucose and ?-1,6-linked glucose being 20 to 30% and 15 to 25%, respectively.Type: GrantFiled: September 18, 2013Date of Patent: August 22, 2017Assignees: Mitsui Sugar Co., Ltd., The Kitasato InstituteInventors: Haruki Yamada, Hiroaki Kiyohara, Kazuhiko Otoguro, Aki Ishiyama, Masato Iwatsuki, Satoshi Omura, Masami Mizu, Toshikazu Kawai, Jun Kashimura, Kenji Koge
-
Publication number: 20170204390Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: ApplicationFiled: January 17, 2017Publication date: July 20, 2017Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, The Kitasato Institute, MONTEFIORE MEDICAL CENTER, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERISTYInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
-
Publication number: 20170204114Abstract: This invention provides a novel non-natural pharmaceutical compound having a different mechanism than statin drugs and having a selective inhibitory activity against ACAT2.Type: ApplicationFiled: June 18, 2015Publication date: July 20, 2017Applicant: School Juridical Person Kitasato InstituteInventors: Hiroshi Tomoda, Masaki Ohtawa, Satoshi Omura, Tohru Nagamitsu
-
Publication number: 20170199143Abstract: A detection device includes: a frequency property acquisition unit that acquires a frequency property when an alternating-current signal is input to at least two conductive bodies provided on a fiber sheet; and a detection signal output unit that outputs a detection signal when the frequency property acquisition unit acquires a predetermined frequency property.Type: ApplicationFiled: April 7, 2015Publication date: July 13, 2017Applicant: School Juridical Person Kitasato InstituteInventor: Satoru NEBUYA
-
Publication number: 20170106093Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: ApplicationFiled: December 21, 2016Publication date: April 20, 2017Applicants: The Board of Trustees of the University of Arkansas, The Kitasato Institute, Montefiore Medical CenterInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
-
Patent number: 9579273Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: GrantFiled: December 14, 2012Date of Patent: February 28, 2017Assignees: The Kitasato Institute, National University Corporation Kagawa UniversityInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
-
Patent number: 9526765Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.Type: GrantFiled: February 11, 2013Date of Patent: December 27, 2016Assignees: The Kitasato InstituteInventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
-
Patent number: 9187492Abstract: A compound effective in prevention and treatment of arteriosclerosis with a mechanism different from that of statin drugs has the following formula or a pharmaceutically acceptable salt, solvate, or hydrate thereof: wherein R1 is an aliphatic, alicyclic, or aromatic acyloxy group, or a group of the formula —O—CH(R7)—R8 where R7 is a lower alkoxy group and R8 is an aryl group, and R2 is carboxyl, a lower alkoxycarbonyl group, or an arylmethylcarbamoyl group, or a —CH2-acyloxy group and R3 is an aliphatic, alicyclic or aromatic acyloxy group, provided that at least one of R4 and R3 is a group other than acetoxy, or R2 and R3 taken together form a group of the formula —O—CH(R5)—O— where R5 is an aryl group.Type: GrantFiled: March 25, 2011Date of Patent: November 17, 2015Assignee: School Juridical Person Kitasato InstituteInventors: Hiroshi Tomoda, Tohru Nagamitsu, Daisuke Matsuda, Taichi Ohshiro, Masaki Ohtawa, Satoshi Omura
-
Patent number: 9101556Abstract: Treatment for alleviating ischemia-reperfusion injury which has minimized risk of side effects and which can suppress neutrophilic infiltration and activation of platelets during ischemia reperfusion comprises administration by inhalation of a mixed gas comprising 21%-98% oxygen, 0.1%-4% hydrogen, 40-80 ppm nitrogen monoxide, and a remainder of inert gas such as nitrogen or helium to a patient undergoing reperfusion from immediately before the start of ischemia reperfusion until shortly after the start of reperfusion.Type: GrantFiled: March 2, 2011Date of Patent: August 11, 2015Assignee: The Kitasato InstituteInventors: Hirosuke Kobayashi, Toshihiro Shimbo, Kenichi Kokubo